Equities Analysts Issue Forecasts for TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Cantor Fitzgerald increased their FY2025 earnings per share estimates for Taysha Gene Therapies in a research note issued on Thursday, February 27th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.38) per share for the year, up from their prior estimate of ($0.40). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group upped their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $1.63 on Monday. The business’s 50-day moving average price is $1.66 and its two-hundred day moving average price is $1.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The company has a market capitalization of $334.06 million, a P/E ratio of 2.59 and a beta of 0.92.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently bought and sold shares of TSHA. Octagon Capital Advisors LP boosted its position in Taysha Gene Therapies by 128.6% in the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock valued at $18,078,000 after buying an additional 5,877,778 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Taysha Gene Therapies in the 4th quarter valued at $8,650,000. Bank of America Corp DE boosted its position in Taysha Gene Therapies by 1,178.9% in the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock valued at $2,959,000 after buying an additional 1,576,568 shares during the last quarter. Norges Bank bought a new position in Taysha Gene Therapies in the 4th quarter valued at $2,528,000. Finally, Avoro Capital Advisors LLC boosted its position in Taysha Gene Therapies by 7.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock valued at $34,600,000 after buying an additional 1,349,999 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.